UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 14, 2021

Medicine Man Technologies, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ☒              

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 14, 2021, the board of directors of Medicine Man Technologies, Inc. (the “Company”) increased the size of the board of directors from five to seven directors, designated the two new directorships as Class A, and appointed Jeffrey A. Cozad and Salim Wahdan as Class A directors. The term of Class A directors expires at the Company’s 2021 annual meeting of stockholders. Mr. Cozad will serve as a member of the board of directors’ Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. Mr. Wahdan will serve as a member of the board of directors’ Audit Committee.

Mr. Cozad was designated for appointment to the Company’s board of directors by CRW Capital Cann Holdings, LLC (“CRW”) pursuant to the terms of the letter agreement between the Company and CRW, dated February 26, 2021 (the “CRW Agreement”), which provides that, for as long as CRW meets the Ownership Threshold (as defined in the CRW Agreement), the Corporation shall take all actions to ensure that one individual designated by CRW shall be appointed to the Company’s board of directors. Among other terms of the CRW Agreement, the Company will pay CRW a monitoring fee equal to $150,000, payable to CRW Capital, LLC in monthly installments of $10,000. The Company previously reported the terms of the CRW Agreement in the Company’s Current Report on Form 8-K filed March 4, 2021 and attached a copy of the CRW Agreement as Exhibit 10.2 thereto, and such disclosure and exhibit are incorporated by reference herein. As previously reported, on February 26, 2021, the Company entered into a Securities Purchase Agreement (the “CRW Purchase Agreement”) with CRW pursuant to which the Company issued and sold 25,350 shares of the Company’s Series A preferred stock (the “Preferred Stock”) to CRW at a price of $1,000 per share for aggregate gross proceeds of $25,350,000. Mr. Cozad is a manager of CRW Capital, LLC, which is the sole manager of CRW and owns a carried interest in CRW, and he shares voting and disposition power of the shares of Preferred Stock held by CRW. Mr. Cozad owns 50% of CRW Capital, LLC. Mr. Cozad and his family members indirectly own membership interests in CRW. The Company previously reported the terms of the CRW Purchase Agreement in the Company’s Current Report on Form 8-K filed March 4, 2021 and attached a copy of the CRW Agreement as Exhibit 10.1 thereto, and such disclosure and exhibit are incorporated by reference herein.

Mr. Wahdan was designated for appointment to the Company’s board of directors jointly by Brian Ruden and Naser Joudeh pursuant to the terms of the Omnibus Amendment No. 2 to Asset Purchase Agreements among the Company and the sellers party thereto, dated December 17, 2020 (the “Star Buds Agreement”), which provides that, for as long as the Sellers (as defined in the Star Buds Agreement) and the Members (as defined in the Star Buds Agreement) meet a specified ownership threshold, the Company shall recommend to its board of directors that Brian Ruden and Naser Joudeh jointly be permitted to designate up to three directors for appointment to the board of directors if the board of directors consists of seven or more members. The Company previously reported the terms of the Star Buds Agreement in the Company’s Current Report on Form 8-K filed December 23, 2020 and attached a copy of the Star Buds Agreement as Exhibit 2.1 thereto, and such disclosure and exhibit are incorporated by reference herein. Mr. Wahdan is a manager of one of the Company’s dispensaries and earns an annual salary in such role.

The Company’s current policy is to award each director an annual grant of shares of the Company’s common stock worth $50,000 and the Company expects to make such awards to Messrs. Cozad and Wahdan in the future.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Apr 2022 to May 2022

Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From May 2021 to May 2022